You are here

  • Home
  • Online First
  • Human papillomavirus genotyping for predicting disease progression in women with biopsy-negative or cervical intraepithelial neoplasia grade 1 of low-grade intraepithelial lesion cytology

Article Text

Article menu

other Versions

Download PDFPDF
Original research
Human papillomavirus genotyping for predicting disease progression in women with biopsy-negative or cervical intraepithelial neoplasia grade 1 of low-grade intraepithelial lesion cytology
  1. Woo Dae Kang,
  2. U Chul Ju and
  3. Seok Mo Kim
  1. Department of Obstetrics and Gynecology, Chonnam National University Medical School, Gwangju, Korea (the Republic of)
  1. Correspondence to Seok Mo Kim, Department of Obstetrics and Gynecology, Chonnam National University Medical School, Gwangju, 61469, Korea (the Republic of); seokmo2001{at}hanmail.net

Abstract

Objective Our study used human papillomavirus (HPV) genotyping to assess the disease occurrence probability in women with a low-grade squamous intraepithelial lesion (LSIL) without histologically confirmed cervical intraepithelial neoplasia grade 2 or worse (CIN2+).

Methods This study investigated CIN2+ incidence in 1986 women from January 2005 to August 2016, including 1123 with LSIL who were histology-proven negative and 863 with LSIL who were histology-proven CIN1. Baseline high-risk HPV (HR-HPV) status was determined using the hybrid capture II assay (HC2), and HR-HPV genotype was determined using the HPV DNA chip test (HDC).

Results Among 1986 women, the HC2 yielded positive results in 1529 (77.0%), while the HDC identified 1624 (81.8%). Thus, the overall HDC and HC2 agreement was 93.2%. Overall, 169 (8.5%) patients developed CIN2+. The 5-year cumulative CIN2+ incidence rates for HPV-16, HPV-18, HPV-31, and HPV-33 were 11.8%, 9.9%, 16.3%, and 16.1%, respectively. Multivariate analysis revealed that HPV-16 (HR 1.637, 95% CI 1.064 to 2.520, p=0.025), HPV-31 (HR 1.845, 95% CI 1.051 to 3.238, p=0.033), and HPV-33 (HR 2.272, 95% CI 1.235 to 4.183, p=0.008) were significantly associated with CIN2+ development.

Conclusion Among women with LSIL, those who test positive for HPV-16, HPV-31, or HPV-33 may require more rigorous follow-up because of a higher CIN2+ risk.

  • Cervical Cancer
  • Cervix Uteri

Data availability statement

Data are available upon reasonable request.

https://doi.org/10.1136/ijgc-2023-004902

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    Data are available upon reasonable request.

    View Full Text

    Footnotes

    • Contributors WDK: Conceptualization, data collection, statistical analysis, investigation, writing - original draft preparation, review and editing, funding acquisition. UCJ: Conceptualization, data collection, statistical analysis, investigation, writing - original draft preparation, review and editing, literature search. SMK: Conceptualization, investigation, writing - original draft preparation, review and editing. All authors read and approved the final manuscript. WDK, UCJ, and SMK are responsible for the overall content as guarantors.

    • Funding This study was supported by a grant (HCRI 23003) from the Chonnam National University Hwasun Hospital Institute for Biomedical Science.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.